---
schema_version: "secwatch.filing_event.v1"
accession: "0001285550-23-000096"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T00:57:05.081526+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q2 revenue record $6.0M (+14% YoY); biologics growth 40%; reaffirms FY guide $25-27M

## Summary
- Record Q2 revenue $6.0M, up 14% YoY; biologics & drug delivery revenue $3.4M (+40%).
- Gross margin fell to 53% from 63% due to lower-margin preclinical services and facility transition costs.
- Operating expenses rose to $10.3M from $7.5M on higher headcount, stock comp, and product development.
- Cash & equivalents $26.5M at June 30, down from $37.5M at Dec 2022; operating cash burn $10.8M.
- Reaffirmed FY2023 revenue guidance $25-27M; CEO outlines five key milestones for H2.

## SEC filing metadata
- accession: 0001285550-23-000096
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000096/0001285550-23-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000096/clpt-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001285550-23-000096
- JSON: https://secwatch.observer/filing/0001285550-23-000096.json
- Plain text: https://secwatch.observer/filing/0001285550-23-000096.txt

## Key facts
- Earnings Releases
  ClearPoint Neuro, Inc. reported second quarter ended June 30, 2023 results: revenue record quarterly revenue of $6.0 million. Guidance reaffirmed.
  - Period: second quarter ended June 30, 2023
  - Revenue: record quarterly revenue of $6.0 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: and delivery to the brain, today announced financial results for its second quarter ended June 30, 2023. Second Quarter Highlights • Reported record quarterly revenue of $6.0 million, a 14% year-over-year increase; • Increased biologics and drug delivery revenue to $3.4 million, a 40% year-over-year increase; • Announced an example of a milestone-based
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285550/000128555023000096/0001285550-23-000096-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.